Indeed, five of the six patients with a glioblastoma in our study harbored MGMT promoter methylation (patients #1, #2, #3, #4 and #6), further emphasizing the clinical importance of determining MGMT promoter status as a prognostic indicator in neurooncology. This evidence concerns the gene MGMT and glioblastoma.